Washington,
D.C. 20549
FORM
6-K
REPORT
OF
FOREIGN ISSUER
Pursuant
to Rule 13a-16 or 15d-16 of
the
Securities Exchange Act of 1934
For
the month of August 2005
Commission
File Number 000-51122
pSivida
Limited
(Translation
of registrant’s name into English)
Level
12
BGC Centre
28
The
Esplanade
Perth
WA
6000
(Address
of principal executive offices)
(Indicate
by check mark whether the registrant files or will file annual reports under
cover Form 20-F or Form 40-F).
Form
20-F
ý Form
40-F o
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted
by Regulation S-T Rule 101(b)(1):
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted
by Regulation S-T Rule 101(b)(7):
Indicate
by check mark whether the registrant by furnishing the information contained
in
this Form is also thereby furnishing the information to the Commission pursuant
to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
Yes
o No
ý
If
"Yes"
is marked, indicate below the file number assigned to the registrant in
connection with Rule 12g3-2(b): 82- ___.
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant,
pSivida Limited, has duly caused this report to be signed on its behalf by
the
undersigned, thereunto duly authorized.
| pSivida Limited | ||
| |
|
|
| Date: August 16, 2005 | By: | /s/ Aaron Finlay |
|
Aaron Finlay |
||
| Chief Financial Officer and Company Secretary | ||
EXHIBIT
INDEX
|
EXHIBIT
99.1:
|
pSivida
announces 5th
US
Patent
|
-2-
| ASX/MEDIA RELEASE |
16th
August 2005
|
5th
US Patent Granted
Monodispersed
porous silicon particles
Drug
Delivery Products
Global
nanotechnology company pSivida Limited (ASX:PSD,
NASDAQ:PSDV, Xetra:PSI)
is
pleased to announce that it has been granted a 5th patent in the important
US
market.
US
Patent
Number 6,929,950 provides for the classification of porous silicon into
monodispersed particles with a tight size distribution. The classification
into
defined
size distributions is a
key
attribute of many micro-engineered particle products.
This
patent provides an important manufacturing aspect to the pSivida portfolio
as it
covers additional dimensions in the formulation of drug delivery products.
The
successful manufacture of ‘monodisperse’ systems not only enables improved
control and flexibility in drug delivery to patients but it also makes the
regulatory registration process simpler as the product offers better definition
and less variability.
The
accurate definition of BioSilicon™ particle size and distribution is also
important for achieving better control of biodegradation, a key property
of this
biomaterial. This in turn offers a greater diversity and flexibility in the
formulation of products from this technology platform. This is important
because
improved flexibility in manufacture provides greater commercial opportunity
for
the formulation and delivery of drugs with different characteristics. The
variety of pharmaceuticals in the market requires drug delivery systems to
effectively ‘handle’ drugs as diverse as proteins, peptides, antibodies, DNA as
well as the traditional small chemical entities that make up most of the
products of the pharmaceutical industry.
pSivida
Managing Director Gavin Rezos said, “The granting of this patent is an important
step towards the development of BioSiliconTM
drug
delivery products for commercial applications, pSivida retains an aggressive
patenting strategy to control the use of BioSilicon™ in
healthcare.”
The
pSivida Intellectual Property portfolio consists of 26 patent families, 31
granted patents and over 80 patent applications. pSivida owns all of the
Intellectual Property (royalty free) for the application of
BioSiliconTM.
pSivida
Limited is currently in negotiations to acquire a US based drug delivery
company
with the potential to create a global drug delivery company specializing
in
nanotechnology, with revenues from existing products and generating long-term
value through its diversified late-stage product portfolio.
-ENDS-
Released
by:
|
pSivida
Limited
Brian
Leedman
Investor
Relations
pSivida
Limited
Tel:
+ 61 8 9226 5099
brianl@psivida.com
|
US
Public Relations
Beverley
Jedynak
President
Martin
E. Janis & Company, Inc
Tel:
+1 (312) 9 1100 ext. 12
bjedynak@janispr.com
|
UK
& Europe Public Relations
Mark
Swallow, PhD / Helena Podd
Citigate
Dewe Rogerson
Tel:
+44 (0)20 7638 9571
mark.swallow@citigatedr.co.uk
|
NOTES
TO
EDITORS:
pSivida
Limited
pSivida
is a global nanotechnology company committed to the biomedical sector and
the
development of products in healthcare. The company’s focus is the development
and commercialisation of a modified form of silicon (porosified or
nano-structured silicon) known as BioSilicon™. As a new and exciting
biocompatible material, BioSilicon™ offers multiple potential applications
across the high growth healthcare sector, including controlled release drug
delivery, targeted cancer therapies (including brachytherapy and localized
chemotherapy), tissue engineering and orthopedics. Potential diagnostics
applications are being developed through its subsidiary AION Diagnostics
Limited.
pSivida
owns the intellectual property rights to BioSilicon™ for use in or on humans and
animals. The IP portfolio consists of 26 patent families, 31 granted patents
and
over 80 patent applications. The core patent, which recognises BioSilicon™ as a
biomaterial was granted in the UK in 2000 and in the US in 2001.
pSivida
is listed on NASDAQ (PSDV),
the
Australian Stock Exchange (PSD)
and in
Germany on the Frankfurt Stock Exchange on the XETRA system (German Symbol:
PSI. Securities Code (WKN) 358705).
pSivida’s shares also trade in the United Kingdom on the OFEX International
Market Service (IMS) under the ticker symbol PSD.
pSivida
is a founding member of the NASDAQ Health Care Index and the Merrill Lynch
Nanotechnology Index.
The
Company’s strategic partner and largest shareholder is the QinetiQ group, the
largest science and technology company in Europe. QinetiQ is the former UK
government Defence Evaluation Research Agency and was instrumental in
discovering BioSilicon™. pSivida enjoys a strong relationship with QinetiQ
having access to its cutting edge research and development facilities. For
more
information on QinetiQ visit www.qinetiq.com.
For
more
information visit www.psivida.com
This
document contains forward-looking statements that involve risks and
uncertainties. Although we believe that the expectations reflected in such
forward-looking statements are reasonable at this time, we can give no
assurance
that such expectations will prove to be correct. Given these uncertainties,
readers are cautioned not to place undue reliance on such forward-looking
statements. Actual results could differ materially from those anticipated
in
these forward-looking statements due to many important factors including:
our
failure to develop applications for BioSiliconTM
due to
regulatory, scientific or other issues, our ability to negotiate and consummate
the proposed acquisition, our ability to successfully integrate the targets
operations and employees; the failure of the targets products, including
reduced
revenue and the combined entity’s inability to develop existing or proposed
products. Other reasons are contained in cautionary statements in the
Registration Statement on Form 20-F filed with the U.S. Securities and
Exchange
Commission, including, without limitation, under Item 3.D, "Risk Factors"
therein. We do not undertake to update any oral or written forward-looking
statements that may be made by or on behalf of pSivida.
This
announcement does not constitute an offer of any securities for sale
or the
solicitation of an offer to buy any securities. Any securities offered
may not
be or have not been registered under the US Securities Act of 1933, as
amended,
and may not be offered or sold in the United States absent registration
or an
applicable exemption from registration requirements.